Johnson & Johnson raised U.S. prices on around two dozen drugs, including psoriasis treatment, Stelara, prostate cancer drug, Zytiga, and blood thinner, Xarelto.
Most of the price increases were between 6 percent and 7 percent; the drugmaker said the average list price increase on its drugs will be 4.2 percent this year.
J&J told Reuters it is not planning to raise the prices on any more of its drugs in 2019.
J&J is not alone when it comes to price increases. According to Rx Savings Drugmakers, by January 10, pharmaceutical companies had raised prices on 490 drugs.